Pancreatic cancer is deadly — but a new drug helps patients survive twice as long as they otherwise would. @LisaMJarvis spoke with researchers and found they had goosebumps (via @opinion) https://t.co/DJJMH5Qa7n ...

Core Viewpoint - Can-Fite BioPharma Ltd. announced positive results from its Phase 2a study of Namodenoson for pretreated pancreatic cancer patients, leading to a significant increase in its stock price [1][6]. Group 1: Clinical Trial Results - The Phase 2a study showed that Namodenoson significantly improved overall survival rates among patients, which analysts consider a promising development for the company [2]. - The treatment was reported to be well-tolerated and exhibited a favorable safety profile [2]. - Ongoing survival follow-up indicates that one-third of patients are currently alive at the time of data cut-off, with further survival outcomes expected to mature and be announced at upcoming scientific meetings [3]. Group 2: Future Developments - Can-Fite is expanding its clinical trials to explore the efficacy of Namodenoson in advanced liver cancer [3]. - The company completed patient enrollment for the Phase 2a pancreatic cancer clinical trial in January, with topline efficacy data anticipated in the third quarter of 2026 [4]. Group 3: Intellectual Property and Additional Indications - In February, Can-Fite received a Canadian patent for the use of Namodenoson in reducing fat mass and body weight, providing intellectual property protection as an anti-obesity therapy [5]. - A patient with advanced decompensated liver cirrhosis treated with Namodenoson successfully underwent liver transplantation, indicating potential additional therapeutic applications [5]. Group 4: Stock Performance - Can-Fite's shares rose by 108.00% to $10.40 at the time of publication, trading near its 52-week low of $3.63 [6].

Core Insights - The most significant event anticipated for the year is the readout of the RASolute 302 trial, which compares daraxonrasib monotherapy to chemotherapy in previously treated pancreatic cancer patients, expected in the first half of the year [1] Group 1: Clinical Trials - A total of 5 Phase III studies have been initiated, with 4 focused on pancreatic cancer, which are expected to progress in enrollment this year [2] - Previous data from a small cohort indicated response rates for daraxonrasib monotherapy and daraxonrasib plus chemotherapy in first-line pancreatic cancer [2]

Core Viewpoint - AIM ImmunoTech Inc. has entered into an agreement with Thermo Fisher Scientific to design a Phase 3 clinical trial for its drug Ampligen, aimed at treating late-stage pancreatic cancer, following promising results from the ongoing Phase 2 DURIPANC trial [1][2]. Group 1: Clinical Trial Developments - The Phase 2 DURIPANC clinical trial, which involves Ampligen and AstraZeneca's durvalumab, is showing positive results in terms of Progression-Free Survival (PFS), Overall Survival (OS), and safety [3]. - The DURIPANC study is an exploratory, open-label trial expected to enroll up to 25 subjects, conducted in collaboration with AstraZeneca and Erasmus Medical Center in the Netherlands [3]. Group 2: Company Strategy and Goals - AIM's CEO emphasized the importance of moving forward with the development of Ampligen for pancreatic cancer, highlighting the drug's potential to address a significant unmet medical need [2]. - The company has published an updated corporate presentation outlining its goal for new drug approval for Ampligen, detailing its research and development efforts in pancreatic cancer [2]. Group 3: Product Information - Ampligen (rintatolimod) is described as a dsRNA and highly selective TLR3 agonist immuno-modulator, which has demonstrated broad-spectrum activity in clinical trials [4].

Company Overview - Amplia Therapeutics Limited is an Australian pharmaceutical company focused on developing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis, particularly in fibrotic cancers such as pancreatic and ovarian cancer [5] - Narmafotinib (AMP945) is the company's leading drug, recognized as a best-in-class FAK inhibitor, which is over-expressed in pancreatic cancer and is gaining attention as a drug target for solid tumors [6] AMPLICITY Trial Details - The AMPLICITY trial is investigating the safety, tolerability, efficacy, and pharmacokinetics of narmafotinib in combination with modified FOLFIRINOX in newly diagnosed patients with advanced pancreatic cancer [8] - The trial is designed as a single-arm, open-label study, proceeding in two parts to identify the optimal daily dose of narmafotinib [9][10] - Currently, the trial has initiated two sites in the US (University of California, Irvine and The Cleveland Clinic) and has two sites open in Australia, with three additional US sites expected to open soon [2][3][6] Clinical Trial Progress - The AMPLICITY trial aims to expand the potential patient base significantly, enhancing the company's presence in the US from both clinical and investor perspectives [3] - The trial is being conducted under an open IND from the US FDA, and further information can be found on the trial's website [8][10] - Previous preclinical studies have shown that the addition of narmafotinib to FOLFIRINOX significantly improves survival in animal models of pancreatic cancer compared to FOLFIRINOX alone [11]

Core Insights - ImmunityBio had a remarkable performance in 2025, setting a strong foundation for 2026 [2] Group 1: Company Achievements - The company received approval for its bladder cancer treatment in 2024, which was a significant milestone [3] - In January 2026, ImmunityBio received its J-Code, enabling the commercial team to effectively market their product [4]

Core Insights - Moleculin Biotech, Inc. is collaborating with Atlantic Health to conduct a Phase 1B/2 study of Annamycin for third-line treatment of advanced pancreatic cancer, addressing a significant unmet medical need in this high-mortality disease [1][3][2] Company Overview - Moleculin Biotech, Inc. is a late-stage pharmaceutical company focused on developing drug candidates for hard-to-treat cancers and viral infections, with Annamycin as its lead program [11] - Annamycin is a next-generation anthracycline designed to avoid multidrug resistance and cardiotoxicity, currently in development for relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma lung metastases [11][4] Study Details - The Phase 1B/2 study will evaluate Annamycin's efficacy in advanced pancreatic cancer, with an estimated cost of approximately $1 million for the trial from 2026 to 2030 [3][1] - Atlantic Health will conduct the study, while Moleculin will supply Annamycin and manage the Investigational New Drug Application (IND) with the FDA [3][1] Preclinical Data - Recent preclinical studies suggest that Annamycin targets critical factors in pancreatic cancer, showing a high level of activity against the disease and associated liver metastases [2][3] - The upregulation of topoisomerase II, the primary target of Annamycin, correlates with poor survival in pancreatic cancer patients, validating the target's relevance [3][2] Industry Context - Pancreatic cancer is the cancer with the highest mortality rate globally and has limited treatment options, particularly in the third-line setting where no approved standard of care exists [2][3] - The collaboration aims to drive innovation in pancreatic cancer treatment, addressing a significant gap in available therapies for patients who have progressed beyond first- and second-line treatments [3][2]

Group 1 - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2][3] - The news team covers key finance and investing hubs including London, New York, Toronto, Vancouver, Sydney, and Perth [2] - Proactive focuses on medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [2][3] Group 2 - The team delivers news and insights across various sectors including biotech, pharma, mining, natural resources, battery metals, oil and gas, crypto, and emerging technologies [3] - Proactive adopts technology to enhance workflows and improve content production [4][5] - All content published by Proactive is edited and authored by humans, ensuring adherence to best practices in content production and search engine optimization [5]

Core Insights - Silexion Therapeutics Corp. has released promising preclinical data for its drug SIL204, which shows effective targeting and anti-tumor activity against pancreatic cancer metastasis [1][3][4] Group 1: Study Findings - SIL204 demonstrated successful biodistribution to all major metastatic sites after a single subcutaneous injection at a dose of 5 mg/mouse, which is a mid-range human equivalent dose for planned clinical trials [2][3] - Significant reductions in tumor burden were observed at day 7 across evaluated organs, with statistically significant reductions (p<0.01) noted in the peritoneum, lung, and intestine [3] - The liver, a common site for pancreatic cancer metastasis, also showed measurable tumor burden reduction, validating the drug's potential for clinical application [4] Group 2: Future Plans - The company is expanding tissue culture studies across various cancer types and KRAS mutations to further explore SIL204's pan-KRAS potential, with results anticipated soon [5] - Silexion is on track to initiate Phase 2/3 clinical trials for its dual-route administration approach in the first half of 2026, with regulatory submissions planned for late 2025 and early 2026 [5] Group 3: Financial Actions - Silexion Therapeutics has priced a public offering of 1.5 million shares along with series A and B warrants, each at $4 per share, which will also have an exercise price of $4.00 per share [6] - Following the news, SLXN stock increased by 14.83%, reaching $5.15 [6]

Core Insights - Pancreatic cancer is highly lethal with a five-year survival rate of only 12%, and current first-line chemotherapy regimens show variable efficacy [1][10] - Tempus AI Inc. has developed PurIST, an RNA-based algorithm that classifies pancreatic ductal adenocarcinoma (PDAC) tumors into "classical" or "basal" subtypes, addressing the need for robust biomarkers in therapy selection [2][10] - The global pancreatic cancer treatment market is projected to reach $5.84 billion by 2030, growing at a CAGR of 12.3% from 2025 to 2030, positioning Tempus' PurIST for significant growth [3] Company Developments - Tempus AI recently presented the largest real-world evidence supporting the integration of PurIST into clinical care for advanced PDAC, demonstrating its role in personalizing first-line therapy [4][5] - The findings from the study published in JCO Precision Oncology establish PurIST as both a prognostic and predictive biomarker, enhancing the likelihood of improved survival for patients [5][10] Market Performance - Tempus AI shares have increased by 67.4% over the past year, outperforming the industry growth of 21.4% and the S&P 500's 19.4% [9] - The company currently trades at a forward Price-to-Sales (P/S) ratio of 9.56X, significantly higher than the industry average of 5.88X, indicating a potentially expensive valuation [11] Financial Estimates - Recent estimates indicate a slight downward adjustment in Tempus AI's loss per share for 2025, moving from -0.14 to -0.16 over the past 30 days [12][13]